A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer
Primary Sponsor
Victorian Comprehensive Cancer Centre (VCCC)
Collaborating Groups
Trans-Tasman Radiation Oncology Group (TROG)
Accrual Target
32
Trial Chairperson
Dr Steven David, Peter MacCallum Cancer Centre, VIC
Related Post
October 18, 2022
NINJA Radiation Therapy Trial participant tells his journey to treatment
The journey to becoming the 200th participant for the
September 6, 2022
The gift that kept on giving
The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing
